30Nov 2022
Empagliflozin in Patients with Chronic Kidney Disease

Empagliflozin in Patients with Chronic Kidney Disease

The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are poorly understood. The EMPA-KIDNEY trial was designed to assess the impact of treatment with empagliflozin in a broad range of such patients. A total of 6609 patients underwent randomization. Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.

  • #family health

Like

Save

Share